ABSTRACT AT-1001 [N-(2-bromophenyl)-9-methyl-9-azabicyclo[3.3.1] nonan-3-amine] is a high-affinity and highly selective ligand at a3b4 nicotinic cholinergic receptors (nAChRs) that was reported to decrease nicotine self-administration in rats. It was initially reported to be an antagonist at rat a3b4 nAChRs heterologously expressed in HEK293 cells. Here we compared AT-1001 actions at rat and human a3b4 and a4b2 nAChRs similarly expressed in HEK 293 cells. We found that, as originally reported, AT-1001 is highly selective for a3b4 receptors over a4b2 receptors, but its binding selectivity is much greater at human than at rat receptors, because of a higher affinity at human than at rat a3b4 nAChRs. Binding studies in human and rat brain and pineal gland confirmed the selectivity of AT-1001 for a3b4 nAChRs and its higher affinity for human compared with rat receptors. In patch-clamp electrophysiology studies, AT-1001 was a potent partial agonist with 65-70% efficacy at both human and rat a3b4 nAChRs. It was also a less potent and weaker (18%) partial agonist at a4b2 nAChRs. Both a3b4 and a4b2 nAChRs are upregulated by exposure of cells to AT-1001 for 3 days. Similarly, AT-1001 desensitized both receptor subtypes in a concentration-dependent manner, but it was 10 and 30 times more potent to desensitize human a3b4 receptors than rat a3b4 and human a4b2 receptors, respectively. After exposure to AT-1001, the time to recovery from desensitization was longest for the human a3b4 nAChR and shortest for the human a4b2 receptor, suggesting that recovery from desensitization is primarily related to the dissociation of the ligand from the receptor.
Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs) mediate important functions across the central and peripheral nervous systems. These receptors are pentameric cation channels comprised of 12 subunits, a2-10 and b2-4, the combinations of which define the nAChR subtypes. Although there are a large number of theoretically possible nAChR subtypes, with possibly differing properties and characteristics, the predominant subtypes found in the central and peripheral nervous systems are a4b2*, a7*, and a3b4* (where * indicates that an additional subunit might be incorporated in the receptor). These nAChR subtypes are differentially expressed, with a4b2* and a7* receptors predominating in most areas of the forebrain and a3b4* receptors predominating in certain areas of the midbrain and hindbrain, as well as in the pineal gland, adrenal gland, and most autonomic ganglia (Perry et al., 2002; Hernandez et al., 2004; Gotti et al., 2006; Mao et al., 2006) .
Most known ligands and drugs that target nAChRs have much higher affinity for the a4b2* subtypes, and these receptors appear to be involved in several important functions, including essential aspects of nicotine addiction. However, increasing evidence suggests that the a3b4* subtypes also may be important in nicotine addiction and withdrawal (Salas et al., 2004; Glick et al., 2011; McCallum et al., 2012; Jackson et al., 2013) . Moreover, the genes coding for both of these constituent subunits are part of a gene cluster in which allelic variations have been associated with heavy smoking (Bierut et al., 2007 (Bierut et al., , 2008 Berrettini et al., 2008; Saccone et al., 2009) . The possibility that the a3b4* nAChR subtype contributes to nicotine addiction, and even to other addictions (Muldoon et al., 2014) , as well as its importance in crucial physiologic functions such as ganglionic neurotransmission, underscores the need for selective ligands for this receptor that can be used as research tools and/or eventually as therapeutic drugs.
Recently, a new compound, AT-1001 [N-(2-bromophenyl)-9-methyl-9-azabicyclo [3.3 .1] nonan-3-amine], was found to be a selective, high-affinity ligand at rat a3b4 nAChRs (Toll et al., 2012; Zaveri et al., 2015) . Furthermore, AT-1001 was reported to be a potent antagonist or partial agonist at a3b4 nAChRs (Toll et al., 2012; Zaveri et al., 2015) , and it effectively reduced nicotine self-administration in rats (Toll et al., 2012) . Rat and human nAChR subunits are, in general, very similar, but an important difference between the two species is found within the extracellular D loop of the b4 subunits (Young et al., 2007) . This structural variation confers differences in the pharmacological responses to certain drugs (Young et al., 2007; Zwart et al., 2008; Stokes and Papke, 2012) . To further explore the pharmacological properties of AT-1001, we carried out comparative studies on the pharmacology of binding and function for rat and human a3b4 and a4b2 nAChRs expressed in HEK-293 cells, as well as binding in rat and human brain, which express primarily b2-containing nAChRs, and pineal gland, which express exclusively (rat) or primarily (human) a3b4 nAChRs. Our results indicate that there are substantial species differences in the binding and functional characteristics of AT-1001 at rat and human a3b4 nAChRs and, most important, that AT-1001 is a potent partial agonist with an efficacy of 65-70% at these receptors. In addition, we found that AT-1001 desensitizes both a3b4 and a4b2 nAChRs but is much more potent at the a3b4 subtype.
Materials and Methods
AT-1001 (N-(2-bromophenyl)-9-methyl-9-azabicyclo [3.3 .1] nonan-3-amine) was synthesized as described by Zaveri et al. (2010 Cell Lines. Tissue culture medium and antibiotics were obtained from Invitrogen (Carlsbad, CA), unless otherwise stated. Fetal bovine serum and horse serum were provided by Gemini Bio-Products (Woodland, CA). The cell lines KXa3b42R2 and KXa4b2R2, expressing rat a3b4 and a4b2 nAChRs, respectively, were established and characterized previously (Xiao et al., 1998; Meyer et al., 2001 ). These cell lines were maintained in medium consisting of Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin G, 100 mg/ml streptomycin, and 0.7 mg/ml Geneticin (G418). The cell lines YXa3b4H1 and YXa4b2H1, expressing human a3b4 and a4b2 nAChRs, respectively, were established by introducing human a3 and b4 subunit genes or human a4 and b2 subunit genes into HEK293 cells. These cell lines were maintained in a medium consisting of minimum essential medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin G, 100 mg/ml streptomycin, 0.7 mg/ml G418 (Geneticin), and 0.1 mg/ml hygromycin B.
Brain and Pineal Gland. Frozen rat brains and pineal glands from adult Sprague-Dawley rats (approximately 50% males and 50% females) were purchased from Zivic Miller Laboratories (Portersville, PA). Human frontal cerebral cortex and pineal glands were obtained at autopsy from psychiatrically normal individuals (men, average age 57). All procedures were carried out in compliance with an approved protocol from the University of Mississippi Medical Center Institutional Review Board. Written informed consent was obtained from legally defined next of kin for tissue collection and informant-based retrospective diagnostic interviews. Psychiatric assessments were performed as previously described (Cobb et al., 2013) . Toxicology screens revealed nothing remarkable.
Radioligand Binding. Cells were harvested at 90-100% confluency by first aspirating culture media and replacing it with 25 ml of 50 mM Tris-HCl buffer (pH 7.4), gently scraping cells from the culture flask surface, and centrifuging this cell suspension at 1000g for 10 minutes at 4°C. Cell membrane homogenates were then prepared by first resuspending the whole cells in 50 mM Tris-HCl buffer, homogenizing them with a Polytron homogenizer (Kinematica AG, Luzern, Switzerland), followed by centrifugation at 33,000g for 10 minutes at 4°C. The supernatant was discarded, and the pellet was resuspended in fresh buffer and treated as above two more times. The final pellet was resuspended in 50 mM Tris-HCl buffer and used in subsequent experiments. Brain and pineal glands were homogenized in 50 mM Tris-HCl buffer (pH 7.4) and membranes were then prepared as described above for cells.
Radioligand competition and saturation binding assays were performed with [ 3 H]EB as described previously (Xiao et al., 1998) in 0.25 ml 50 mM Tris-HCl buffer, pH 7.4 at 23°C. The affinities of AT-1001 at the rat and human versions of the a3b4 and a4b2 nAChR subtypes expressed in HEK293 cells were determined in competition binding assays. Cell membrane homogenates were incubated for 4 hours with ∼0.4 nM [ 3 H]EB in the absence or presence of increasing concentrations of AT-1001. The homogenates were then filtered through Whatman GF/C filters (GE Healthcare Life Sciences, Pittsburgh, PA) treated with 0.5% polyethylenimine and counted in a Beckman-Coulter LS6500 Scintillation Counter (Franklin Lakes, NJ). Nonspecific binding was measured in the presence of 300 mM (2)nicotine, and specific binding was defined as the difference between total and nonspecific binding. The AT-1001 binding competition curves were fit to one-site and two-site binding competition models by nonlinear least square regression analysis using GraphPad Prism 5 (San Diego, CA). The K i of AT-1001 at each receptor was then calculated with the Cheng-Prusoff equation (Cheng and Prusoff, 1973) Immunoprecipitation studies with subunit-specific antibodies have established that the heteromeric nAChRs in rat cerebral cortex are predominantly (∼90%) the a4b2 subtype (Whiting et al., 1987; Flores et al., 1992; Mao et al., 2008) , with ∼16% of these receptors also containing an a5 subunit (Mao et al., 2008) . The predominant nAChRs in human cerebral cortex are also the a4b2 subtype (Gotti et al., 2006) . The heteromeric nAChRs in rat pineal gland are virtually all the a3b4 subtype (Hernandez et al., 2004) . The human pineal gland appears to contain the a3b4 nAChR subtype predominantly, but also one that includes the b2 subunit (unpublished data). Therefore, to measure binding competition at the a3b4 subtype alone in human pineal gland, 10 nM sazetidine-A was included in the assay to block binding to essentially all b2-containing nAChRs. Under these conditions, AT-1001 competition curves for [ ]EB was determined in the presence of 300 mM (2)nicotine, and specific binding was defined as the difference between total and nonspecific binding. Free ligand concentrations were adjusted for amount bound, and the receptor densities (B max ) and dissociation constants (K d ) were then determined using nonlinear least-square regression analysis in GraphPad Prism 5.
Upregulation of Nicotinic Receptors. The effect of chronic exposure to AT-1001 on nAChR density was examined by culturing cells for 3 days in media containing either 0, 0.3, or 10 mM AT-1001 or, for comparison, 10 mM (2)nicotine. After 3 days, when the cells were 90-100% confluent, they were collected, homogenized, and washed, as described above, except that the cell membranes were incubated at 37°C for 30 minutes after each homogenization and then centrifuged at 33,000g and resuspended in buffer. This procedure was repeated five times to reduce the possibility of any AT-1001 remaining in the membranes. The cell homogenates were then resuspended, and receptor binding site density was measured with a single, saturating concentration (∼3 nM) of [ 3 H]EB. Electrophysiology. Nicotinic receptor function was evaluated in HEK cell lines in the whole cell voltage-clamp configuration using an Axopatch 200B amplifier (Axon Instruments, Burlingame, CA). Cells plated on a glass coverslip were placed in the recording chamber of a microfluidic chip (Dynaflow Resolve, Cellectricon, Sweden) containing extracellular solution comprised of (in millimolar): 130 NaCl, 5 KCl, 2 CaCl 2 , 2 MgCl 2 , 10 dextrose, and 10 HEPES. Voltage-clamp recordings (V hold 5 270 mV) were made with patch electrodes (5-8 MV) with internal solution (pH 7.2) comprised of the following (in millimolar): 145 K-gluconate, 5 EGTA, 5 MgCl 2 , 10 HEPES, 5 ATP.Na, and 0.2 GTP.Na. Series resistance was typically ,10 MV and was not compensated but was continuously monitored with a hyperpolarizing 5-mV pulse. Generation of voltage-clamp protocols and acquisition of data were carried out using pCLAMP 10 software (Axon Instruments, Inc.). Sampling frequency was 20 kHz and current signals were filtered at 5 kHz before digitization and storage. All experiments were performed at room temperature (23-25°C).
Drug Application. In conjunction with whole cell voltage-clamp recording, drugs were applied to cells via a microfluidic laminar stream solution exchange system (MLSSE; Dynaflow Resolve) as described previously (Fedorov et al., 2012) . Briefly, after establishing a steady-state laminar flow, a drug application protocol was initiated, which consisted of exposing a single voltage-clamped cell to various drugs at the indicated concentrations (200-millisecond drug exposure; 1-minute interstimulus interval). Peak elicited currents in each individual cell were normalized to the peak current elicited by 1 mM ACh in the same cell. This concentration of ACh reliably stimulates maximum currents in these cells.
Rubidium Efflux Assays. The effect of AT-1001 on nAChR function was also examined by assessing 86 
Rb
1 efflux through the receptor channel, as described previously (Xiao et al., 1998; Meyer et al., 2001) . Cells were first loaded with 86 RbCl by incubating them for 2-4 hour with 0.5 ml media containing ∼100,000 dpm 86 Rb 1 . To test agonist activity of AT-1001, the cells were rinsed gently four times with 1 ml buffer over 10 minutes, and then either buffer alone or buffer containing 100 mM nicotine or different concentrations of AT-1001 was added for 2 minutes. The background efflux was determined in the cells that received buffer alone, whereas maximal response was defined as the efflux elicited by 100 mM nicotine. The 86 Rb 1 efflux was assessed using Cerenkov counting on a Beckman-Coulter LS6500 Scintillation Counter. After subtracting background efflux, AT-1001 stimulation was expressed as the percent of efflux elicited by 100 mM nicotine, which stimulates maximum 86 Rb 1 efflux in these cells. To examine concentration-dependent desensitization, cells were loaded with 86 Rb 1 , rinsed gently three times over ∼2 minutes with 1 ml buffer each time, and then treated for 10 minutes with different concentrations of AT-1001 in 0.5 ml buffer. After this 10-minute treatment, the drug-containing buffer was aspirated, and the cells were immediately stimulated with 100 mM nicotine in 0.5 ml buffer for 2 minutes. For analysis, nicotine-stimulated 86 Rb 1 efflux in cells exposed to AT-1001 was compared with stimulated 86 Rb 1 efflux in cells not exposed to AT-1001, which was set as 100%.
Results
Binding of AT-1001 to Human and Rat a3b4 and a4b2 nAChRs Expressed in HEK293 Cells. The binding affinities of AT-1001 were examined in membrane homogenates from four separate HEK293 cell lines expressing either human or rat a3b4 nAChRs or human or rat a4b2 nAChRs. AT-1001 competed effectively with [ 3 H]EB for binding at all of the nAChR subtypes tested. Figure 1 shows the competition curves from a representative experiment, and the results of five such binding studies are summarized in Table 1 . As shown previously (Toll et al., 2012) , AT-1001 competes with much higher affinity for a3b4 than for a4b2 nAChRs. Importantly, however, its affinity for the human a3b4 receptor expressed in these cells is approximately 20-fold higher than its affinity for the rat a3b4 receptor (P , 0.001), whereas its affinities for the human and rat a4b2 nAChRs are similar. Consequently, the relative affinity (selectivity ratio) of AT-1001, calculated as the ratio of its K i for a4b2 nAChRs over its K i for a3b4 nAChRs, is ∼40 for the rat receptors but more than 980 for the human receptors.
Binding of AT-1001 to Human and Rat a3b4 and a4b2 nAChRs in Native Tissues. To determine how closely AT-1001 binding in these heterologously expressed rat and human a3b4 and a4b2 nAChRs corresponds to its binding in native tissues, we examined AT-1001 competition for receptors in rat and human pineal gland, which in the rat are exclusively and in the human predominantly a3b4 receptors, and in rat and human cerebral cortex, which are predominantly a4b2 nAChRs in both species. As shown in Fig. 2 and summarized in Table 2 , consistent with its higher affinity for a3b4 nAChRs, AT-1001 competes with much higher affinity for nAChRs in rat and human pineal gland than for the receptors in rat and human cortex. Interestingly, the affinities of AT-1001 in these native tissues were 8-to 4-fold lower than the affinities found in the HEK cells heterologously expressing the corresponding nAChRs (compare Tables 1 and 2 ). This might be because of differences such as lipids or accessory proteins in the cell types, Table 1 for K i values and selectivity ratios from five similar studies. 
Human a3b4 0.092 6 0.008 989 Human a4b2 9 1 6 8 Rat a3b4
1.9 6 0.1*** 41 Rat a4b2 7 8 6 10 ***The K i value of AT-1001 at the rat a3b4 nAChR is significantly higher than at the human a3b4 receptor (P , 0.001), whereas the K i values at the a4b2 nAChRs are not significantly different from each other. or to differences in the stoichiometry of the receptors expressed in HEK cells versus the native cells. Nevertheless, as shown in Table 2 , the relative selectivity ratio between human pineal (a3b4) and human cortex (a4b2) and rat pineal and rat cortex were similar to the selectivity ratios measured in the heterologously expressed receptors.
To determine the type of mechanism by which AT-1001 inhibits binding at nAChRs, [ 3 H]EB binding saturation curves were compared in the absence and presence of AT-1001. To account for its higher affinity at the human a3b4 receptor, we extended the concentration of [ ]EB saturation curves to the right, consistent with simple competitive inhibition; but at higher concentrations, AT-1001 appeared to also decrease the B max of the saturation curves, which is usually indicative of a noncompetitive mechanism. For example, at the highest AT-1001 concentration used here, the B max of the human a3b4 nAChR was decreased to 28 6 3% of the control B max and it was decreased to about 20% at the rat a3b4 nAChR. Even when the incubation time for the [ 3 H]EB binding assays in the presence of 30 nM AT-1001 was extended to 24 hours to ensure that equilibrium would be reached, the saturation curves were again shifted to the right, but the full B max was still decreased (unpublished data). A possible explanation for the apparent decrease in B max of the a3b4 nAChRs is related to the high affinity of AT-1001, which is similar to that of [ 3 H]EB at these receptors; thus, even at the highest concentration, AT-1001 is probably acting competitively, but at these high concentrations it may simply outcompete [
3 H]EB for rebinding to any unoccupied receptors, resulting in the appearance of a noncompetitive mechanism.
In contrast to its apparently complex binding profile at a3b4 nAChRs, at the a4b2 nAChRs, where it has much lower affinity (and [ (Fig. 3,  C and D) . This right shift, consistent with simple competitive inhibition, was found even in the presence of 30 mM AT-1001, a concentration used to achieve the receptor occupancy at a4b2 nAChRs that would approximate the occupancy by the 30 nM concentration at human a3b4 nAChRs, which have nearly 1000-fold higher affinity.
Upregulation of nAChRs by AT-1001. Chronic administration of most nicotinic agonists and partial agonists in vivo upregulate a4b2 nAChRs in brain (Schwartz and Kellar; Marks et al., 1983 Marks et al., , 2011 Flores et al., 1992; Mao et al., 2008) . In contrast, the a3b4* receptors found in autonomic ganglia, adrenal gland, retina, and pineal gland are not upregulated by chronic nicotine (Flores et al., 1997; Dávila-García et al., 2003) . However, in cell lines that heterologously express various nAChR subunit combinations, a3b4 nAChRs as well as all other putative nAChR subtypes tested are increased by exposure for 1 to 5 days to several nicotinic ligands that bind to the agonist binding site (Wang et al., 1998; Meyer et al., 2001; Xiao and Kellar, 2004) . To determine if AT-1001 also upregulates heterologously expressed nAChRs, we measured [ 3 H]EB binding to human a3b4 and a4b2 nAChRs from cells treated for 3 days with 0.3 or 10 mM AT-1001, concentrations that would be expected to occupy virtually all a3b4 nAChRs and 77 or 99% of the a4b2 nAChRs. These treatments upregulated both the a3b4 and a4b2 nAChRs (Fig. 4) . The a3b4 receptors were increased approximately 2-fold by AT-1001 at both the 0.3 and 10 mM concentrations, similar to the increase induced by 10 mM nicotine. The a4b2 nAChRs, which are more responsive than a3b4 receptors to upregulation by agonists, were increased 2-fold by the 0.3 mM concentration of AT-1001 but 6-fold by the 10 mM concentration. The increase in a4b2 nAChRs induced by 10 mM AT-1001 was similar to that induced by 10 mM nicotine (Fig. 4) .
Agonist Activity of AT-1001. Agonist activity of AT-1001 at nAChRs was determined in patch-clamp electrophysiology studies and 86 Rb 1 efflux studies. Examples of the response traces elicited by AT-1001 in patch-clamp experiments with human and rat a3b4 and human a4b2 receptors are shown in Fig. 5A . AT-1001 concentration-response curves for these three receptors are shown in Fig. 5B and summarized in Table 3 . The responses elicited by AT-1001 were normalized to the response of each cell to 1 mM ACh, which reliably elicited maximum responses in these cells. AT-1001 demonstrated 65-70% partial agonist activity at the two a3b4 nAChRs and 18% agonist activity at the human a4b2 receptor (see legend to Fig. 5 for the maximal current responses for each of these receptors). It also showed partial agonist activity at rat a4b2 receptors, but because these receptors have a low maximal response to 1 mM ACh (E max 5 48 6 7 pA, n 5 3) and an even lower response to AT-1001 (E max 7.2 6 5 pA), we could not determine a reliable EC 50 value for AT-1001 at this rat receptor. Table 2 for K i values and selectivity ratios from 2 to 3 similar studies. Values are the mean 6 standard error of 2 independent assays for pineal and 3 for cortex.
Human pineal 1.2 6 0.6 917 Human cortex 1100 6 300 Rat pineal 16 6 1** 69 Rat cortex 1100 6 90 **The K i value of AT-1001 at the rat pineal nAChR is significantly higher than at the human pineal nAChR (P , 0.01), whereas the K i values at the human and rat cortex nAChRs do not differ.
As shown in Table 3 , of the three receptors at which we were able to calculate EC 50 values in these patch-clamp studies, AT-1001 has the highest potency at human a3b4 receptors (EC 50 5 0.4 mM); its next highest potency is at rat a3b4 (EC 50 5 1.4 mM), and its lowest potency is at human a4b2 receptors (EC 50 5 4.3 mM). Thus, the agonist potency of AT-1001 is 3 times higher at human a3b4 nAChRs than at the rat version, and it is ∼10 times higher than at human a4b2 nAChRs.
Responses elicited by AT-1001 in 86 Rb 1 efflux studies were normalized to the responses elicited by 100 mM nicotine; these nicotine-stimulated responses are shown in Fig. 6A . Consistent with the electrophysiological measurements, AT-1001 demonstrated partial agonist activity in these 86 Rb 1 efflux measurements at both human and rat a3b4 receptors (Fig.  6B) . Although nicotine reliably induces 86 Rb 1 efflux via the human a4b2 nAChR channels (see Fig. 6A ), AT-1001 did not induce a measurable response in these receptors with this assay. Neither nicotine nor AT-1001 elicited responses at the rat a4b2 receptor in this cell line. The EC 50 and E max values for the human and rat a3b4 receptors calculated from these 86 Rb 1 efflux studies are summarized in Table 3 . Consistent with the electrophysiological studies, AT-1001 demonstrated significantly higher potency at the human a3b4 nAChR than at the rat receptor (P , 0.01). In these 86 Rb 1 efflux assays, the E max value for the human receptor was significantly greater than for the rat receptor (P , 0.01).
Desensitization. Nicotinic agonists and partial agonists induce nAChR desensitization, which appears to depend primarily on a ligand's occupancy of the agonist binding site rather than its efficacy at the receptor. The potencies of AT-1001 to desensitize human and rat a3b4 nAChRs and human a4b2 nAChRs were determined using the 86 Rb 1 efflux assay, which we find is a more suitable method than patch clamp for assessment of desensitization because it measures the responses in a large population of cells. Thus, nicotinestimulated 86 Rb 1 efflux was measured immediately after a 10-minute exposure to different concentrations of AT-1001. The 10-minute exposure to the highest concentrations of AT-1001 fully desensitized all three nAChRs tested, but the desensitization potency of AT-1001 varied across the receptors ( Fig. 7; Table 4 ). The concentration that decreased the nicotine-stimulated 86 Rb 1 -efflux response by 50% is referred to here as the DC 50 .
The order of potency for desensitization of these three receptors followed the same order of potency for activating the receptors and as the affinity for binding; but in the studies that allowed accurate assessments of the EC 50 values (all three receptors in patch-clamp studies and two of the three receptors in 86 Rb 1 efflux assays), the potencies to desensitize the receptors were closer to the potencies to activate than to the affinities for the agonist binding sites. Thus, under these conditions, the DC 50 concentrations of AT-1001 were similar to its EC 50 for activation at each of these receptors; whereas in contrast, these DC 50 concentrations of AT-1001 were 1200 to 600 times higher than its binding K i values at the human and rat a3b4 receptors, respectively, and 36 times higher than the K i at the human a4b2 receptor. It should be noted, however, that the similarities between the potencies to desensitize and to activate may, at least in part, reflect the similar incubation times under which the measurements were made, i.e., seconds and minutes for activation and desensitization, compared with hours for equilibrium binding.
As shown in Table 4 , the Hill slopes for these desensitization measurements at the human a3b4 and a4b2 receptors were statistically greater than 1 (P , 0.01), whereas measurement at the rat a3b4 receptors trended in that direction (P , 0.1). This suggests that desensitization involves more Fig. 5 . AT-1001 is a partial agonist at human a3b4, rat a3b4, and human a4b2 nAChRs as assessed with patch-clamp electrophysiology. (A) Representative whole cell current traces elicited by AT-1001 from human and rat a3b4 and human a4b2 nAChRs expressed in HEK cells (the horizontal bar = 1-second drug application). (B) Concentration-response curves of AT-1001 stimulated currents in the three nAChRs. The points in the curves were normalized to 1 mM ACh and are the mean 6 S.E.M. of 6-9 experiments. The maximal responses to 1 mM ACh for human and rat a3b4 and human a4b2 nAChRs were, respectively: 1142 6 246, 1648 6 382, and 312 6 129 pA. See Table 3 for the EC 50 values. (The maximal response of rat a4b2 receptors to 1 mM ACh was 48 6 7 pA, and the response to AT-1001 was only 7.2 pA, which was considered too small for a reliable calculation of an EC 50 value for AT-1001.). Human a3b4 0.46 0.1** 70 6 6** 1.8 6 0.2* 0.1 6 .003** 59 6 0.3** 2.0 6 0.2* Rat a3b4
1 . 46 0.2** 65 6 4** 1.8 6 0.1* 1.5 6 0. N.D., not determined because responses to AT-1001 at rat a4b2 receptors in patch clamp studies and at both rat and human a4b2 receptors in 86 Rb + -efflux studies were too small to calculate a reliable EC 50 . **In patch clamp studies, the EC 50 values are statistically different from one another (P , 0.01); and the E max values for both human and rat a3b4 nAChRs are statistically greater than the values for the human a4b2 receptors (P , 0.01). In the 86 Rb + -efflux studies, both the EC 50 and the E max values for human a3b4 receptors are statistically different from the rat receptors (P , 0.01).
*The Hill coefficients are statistically greater than 1 (P , 0.05).
than simple receptor occupancy by a ligand at a single site; it could, for example, indicate that two or more binding sites have to be occupied to induce full desensitization and that there is a cooperative step in the process.
AT-1001 at high concentrations completely desensitizes all of these nAChRs (Fig. 7) . To determine the rates of recovery from AT-1001-induced desensitization for each receptor subtype, we measured responses to ACh using the patch-clamp method because it allows a high degree of temporal resolution. Responses to 1 mM ACh in cells expressing human or rat a3b4 or human a4b2 receptors were recorded, and the cells were then exposed for 10 minutes to AT-1001 at a concentration equal to 100 times its DC 50 . After a rapid wash in buffer, the cells were exposed to a rapid pulse of 1 mM ACh each minute followed by a wash in buffer to observe the recovery of function for up to ∼35 minutes. As shown in Fig. 8 , the human a4b2 receptors display the fastest rate of recovery, with a half-time for recovery of 0.68 minute; the rat a3b4 receptors recovered next fastest, with a half-time of 3.3 minutes, and the human a3b4 receptors displayed the slowest rate of recovery, with a half-time of 9.7 minutes. These results suggest that the rate of recovery from desensitization after exposure to AT-1001 is a function of the binding affinity of the ligand-that is, directly related to its dissociation rate.
Discussion
AT-1001 is likely to be an important tool for studying nAChRs because it is the first ligand with high selectivity for a3b4 nAChR binding sites. Nevertheless, in assigning nAChR subtype(s) that mediate the effects of AT-1001, especially its effects in vivo, it is important to have as complete a pharmacological profile as possible.
Our results confirm earlier studies that AT-1001 binds with high affinity and selectivity to a3b4 nAChRs (Toll et al., 2012) and that it displays partial agonist activity (Zaveri et al., 2015) . In HEK cells heterologously expressing the rat versions of the a3b4 and a4b2 nAChR subtypes, we found that AT-1001 displays 41-fold selectivity for the a3b4 subtype, which also is in general agreement with the initial report (Toll et al., 2012) . Interestingly, however, in cells expressing the human versions of these nAChR subtypes, AT-1001 exhibits nearly 1000-fold selectivity for the a3b4 subtype. This was due to approximately 20-fold higher affinity of AT-1001 for the human than for the rat a3b4 receptor, while exhibiting similar affinities for the heterologously expressed rat and human a4b2 receptors.
To further explore this difference between rat and human nAChRs, we compared the affinities of AT-1001 in rat and human pineal gland, which under the conditions used here represent nearly exclusively the a3b4 nAChR subtype, and rat and human cerebral cortex, which represent predominantly ($90%) the a4b2* nAChR subtype. Although the binding affinities of AT-1001 for the heterologously expressed receptors and their corresponding subtypes in native tissues differed, possibly because of different subunit stoichiometries or differences in accessory proteins or lipids between the cells in native tissues and HEK cells, the selectivity of AT-1001 for a3b4 nAChRs was still very clear; in fact, the selectivity of AT-1001 for both human and rat a3b4 over a4b2 nAChRs was similar in the native tissues and in the cell lines.
An iodinated analog of AT-1001, [ 125 I]AT-1012, was recently synthesized and shown to be an excellent radioligand for autoradiography studies of a3b4 nAChRs in rat brain (Wu et al., 2014) . If the same difference in affinity between human and rat a3b4 nAChRs holds for [
125 I]AT-1012, it should be an Rb + efflux at human a4b2 nAChRs (see A), AT-1001 did not elicit a measurable response at these receptors in this assay. Curves are representative of 3 or 4 independent experiments. See Table 3 for EC 50 and E max values. Fig. 7 . AT-1001 potently desensitizes human and rat a3b4 and human a4b2 nAChRs. Desensitization was determined in 86 Rb + -efflux measurements after a 10-minute exposure to AT-1001 at the concentrations shown. Values are the mean 6 S.E.M. from 3 or 4 independent measurements. Where no S.E.M. bar is evident, it is within the symbol. See Table 4 for the calculated parameters from these curves.
even better probe for a3b4 nAChRs in human central nervous system and peripheral tissues, where the density of nAChRs is much lower than in these cell lines.
At low concentrations of AT-1001 (up to about 3 nM), there is a clear rightward shift of [ 3 H]EB saturation curves, consistent with a competitive mode of inhibition; but at higher concentrations of AT-1001 (30 and 300 nM), which are approximately 300 times and 150 times its K i at human and rat a3b4 nAChRs, respectively, there is also an apparent decrease in the B max of binding, suggesting a noncompetitive mode of inhibition at the receptor. However, this more likely results from a very slow dissociation rate of AT-1001 at a3b4 nAChRs, which would be consistent with its very high affinity and the high concentrations of AT-1001 out-competing The initial paper describing AT-1001 pharmacology determined that it was a selective antagonist at rat a3b4 nAChRs (Toll et al., 2012) . In contrast, we found that it is a potent and relatively efficacious partial agonist at both human and rat a3b4 nAChRs. Its efficacy relative to ACh was 65-70% in whole cell patch-clamp measurements and 36-59% relative to nicotine in 86 Rb 1 efflux assays. The difference between the efficacies found in these two types of assays may be related to receptor desensitization, which is more evident during the much longer stimulation period required in the 86 Rb 1 efflux assay than in patch-clamp measurements (see below). In our patch-clamp measurements of human a3b4 nAChRs expressed in HEK cells, AT-1001 displayed a potency of 0.4 mM, which is nearly identical to the potency found in a recent study in Xenopus oocytes expressing human a3b4 nAChRs (Zaveri et al., 2015) . The potency of AT-1001 was 3.5-fold higher at the human than the rat a3b4 receptor in patchclamp measurements and 15-fold higher in 86 Rb 1 efflux assays. These species differences in AT-1001 agonist potencies are consistent with, although somewhat lower, than its 21-fold difference in binding affinity at these a3b4 receptors. AT-1001 also displayed partial agonist activity at the human a4b2 nAChR in patch-clamp studies, but its efficacy was only 18% of the ACh response and its potency was 10-times lower than at the human a3b4 receptor.
The differences in binding and function of AT-1001 at the a3b4 and a4b2 nAChRs probably reflect the strong influence of both the a and b subunits on the pharmacology of nAChRs (Luetje and Patrick, 1991; Papke and Heinemann, 1994; Parker et al., 1998) , whereas the differences between the human and rat a3b4 nAChRs may result from differences in two adjacent amino acids within the extracellular D loop of the b4 subunit (Young et al., 2007) . Several other drugs have now been found to display differences in affinity, potency, and/ or efficacy between human and rat a3b4 nAChRs (Young et al., 2007; Zwart et al., 2008; Stokes and Papke, 2012) .
AT-1001 has one of the highest affinities for a3b4 nAChRs that has been reported, similar to or only slightly lower than the affinity of epibatidine for these receptors. In contrast, its affinity for the a4b2 subtype is one to three orders of magnitude lower than such ligands as nicotine, cytisine, A-85380 [3-((2S)-azetidinylmethoxy)pyridine dihydrochloride], and epibatidine. Despite this difference in binding affinity at these two receptors, a 3-day incubation of cells with AT-1001 at concentrations designed to occupy nearly all of the a3b4 and most of the a4b2 receptors increased both receptor subtypes. Both the lower (0.3 mM) and higher (10 mM) concentrations of AT-1001 increased human a3b4 nAChRs by about 2-fold, which was similar to the increase induced by 10 mM nicotine measured here, as well as in rat a3b4 receptors expressed in HEK cells in previous studies (Meyer et al., 2001; Xiao and Kellar, 2004) . In contrast, although incubation with 0.3 mM AT-1001 increased human a4b2 nAChRs approximately 2-fold, incubation with 10 mM AT-1001 increased these receptors approximately 6-fold, which was similar to the increase induced by 10 mM nicotine. Thus, despite its much higher affinity for a3b4 nAChRs, AT-1001 can clearly affect the regulation of a4b2 receptors as well. These results are consistent with the idea that occupancy of the receptor's orthosteric binding site, independent of channel function, is the trigger for upregulation in these cells. However, because there appear to be differences between the mechanisms for upregulation of nAChRs in heterologous systems and neurons (Lomazzo et al., 2011) , it is not known whether AT-1001 would upregulate either a3b4 or a4b2 nAChRs in vivo. Desensitization of the receptor responses to 100 mM nicotine was determined after exposing cells to AT-1001 for 10 minutes at concentrations of 1 nM to 100 mM (see Fig. 7 ). The DC 50 is the concentration of AT-1001 that decreases the response to nicotine by 50%.
DC 50
Hill Slope mM Human a3b4 0.11 6 0.01** 1.4 6 0.05** Rat a3b4
1 . 2 6 0.1** 1.5 6 0.2 Human a4b2 3 . 3 6 0.4** 1.6 6 0.1** **The differences between the DC 50 values among the three receptors are all statistically significant, (P , 0.01). The Hill coefficients for human a3b4 and a4b2 receptors are greater than 1 (P , 0.01). The Hill coefficient for rat a3b4 was not statistically different from 1, but trended in that direction (P , 0.1). Fig. 8 . Recovery of function of nAChRs measured by patch-clamp electrophysiology after desensitization. Currents stimulated by 1 mM ACh were measured each minute after a 10-minute exposure to AT-1001 at a concentration 100 times the DC 50 of the respective receptor (shown in the figure inset). Results were normalized to the maximal response to 1 mM ACh in the cells before exposure to AT-1001. Each curve fit to a one-phase exponential model with a t 1/2 of 9.7 minutes, 3.3 minutes, and 0.68 minutes for human a3b4, rat a3b4, and human a4b2 receptors, respectively. The points in the curves represent the mean 6 S.E.M. of 3-5 experiments.
Nicotinic agonists desensitize nAChRs. Moreover, nicotine is usually 10 to 40 times more potent to desensitize than to activate nAChRs, both in vivo (Sharp and Beyer, 1986; Hulihan-Giblin et al., 1990 ) and in vitro Marks et al., 1994; Lester and Dani, 1995; Meyer et al., 2001) . In contrast, the potencies of AT-1001 to desensitize both a3b4 and a4b2 nAChRs are similar to its potencies to activate these receptors. Although this apparent difference between AT-1001 and other nicotinic ligands might be due to the time frame or other conditions of the measurements, it also suggests that the mechanisms triggering or underlying nAChR desensitization might differ among ligands. The Hill slopes for desensitization of human a3b4 and a4b2 nAChRs were significantly greater than 1, and that for rat a3b4 nAChRs trended in that direction, suggesting that desensitization might involve more than one step and include a cooperative process, such as binding of the ligand to a second orthosteric site or, less likely, to an allosteric site.
Although the DC 50 values of AT-1001 for desensitization by AT-1001 are similar to its EC 50 values for activation at each of the three receptors, the time to recovery from desensitization follows the reverse order of its binding affinity; thus, the receptor with the highest affinity recovers slowest and the receptor with the lowest affinity recovers fastest. This is consistent with the time to recovery from desensitization being dependent on the dissociation of the ligand from the receptor. The a4b2 nAChR subtype is usually found to exhibit the longest recovery times after desensitization, and our data here suggest this is probably a function of the slower dissociation rates of most nicotinic ligands, which usually have highest affinity at a4b2 nAChRs. AT-1001 is clearly an exception.
In conclusion, we examined the binding affinities and functional effects of AT-1001 at human and rat a3b4 and a4b2 nAChRs, as well as its effects on the regulation of these receptors. We found AT-1001 to be a 65-70% partial agonist at a3b4 nAChRs, with higher binding affinity and potency at the human than the rat version of these receptors. Moreover, it is highly selective in its binding affinity (989-fold), its functional potency (10-fold), and its desensitization potency (30-fold) for human a3b4 over a4b2 nAChRs.
